Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium*

OBJECTIVES: The long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237) has recently been approved as a once-daily treatment for COPD. The objectives of this study were to determine the dose delivery characteristics of glycopyrronium and compare them with those of the LAMA tiotropium, both...

Descripción completa

Detalles Bibliográficos
Autores principales: Colthorpe, Paul, Voshaar, Thomas, Kieckbusch, Thomas, Cuoghi, Erika, Jauernig, Juergen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Maney Publishing 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937662/
https://www.ncbi.nlm.nih.gov/pubmed/27536432
http://dx.doi.org/10.3109/21556660.2013.766197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937662/
https://www.ncbi.nlm.nih.gov/pubmed/27536432
http://dx.doi.org/10.3109/21556660.2013.766197

Ejemplares similares